Nasdaq Biotechnology Ishares (IBB) 233.28 $IBB
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - ZACKS - Mon May 05, 1:49AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Pharma ETFs: A Safe Haven from the Biotech Stock Slump? - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Apr 28, 10:42AM CDT
Why investors may want to think about a play on the pharmaceutical ETFs if they want drug industry exposure.
iShares Nasdaq Biotechnology Index Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.46% Loss
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs.
Pharma ETFs: A Better Healthcare Investment? - Video Blog
Eric Dutram - Zacks Investment Research - Wed Apr 23, 5:42PM CDT
How have pharma ETFs held up during the biotech selloff?
iShares Nasdaq Biotechnology Index Fund (IBB) : Buy @ $231.17
Trading Central - Tue Apr 22, 8:43AM CDT
From a technical view, the ETF is bouncing off a key rising trend line drawn from the bottom of October 2012. Regarding technical indicators, the weekly RSI is pushing above its 50 mark while the 20-week moving average is reversing up. On a...
'Fast Money' Recap: Following the Netflix Story
at The Street - Tue Apr 22, 4:00AM CDT
The trading panel discussed Netflix earnings and Valeant's hostile bid for Allergan.
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 2.33%
Comtex SmarTrend(R) - Mon Apr 21, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $221.37 to a high of $227.34. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $226.39 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
The ongoing market correction has taken a serious toll on biotech stocks, especially among companies early in their development. The iShares Nasdaq Biotech Index , for instance, is down over 15% in the past month alone. Market corrections (and bull...
'Fast Money' Recap: Watch Where Bonds Are Headed
at The Street - Fri Apr 18, 4:00AM CDT
The trading panel discussed bonds, industrial stocks, Chipotle Mexican Grill and IBM.
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's...
IBB, CELG, BIIB, ALXN: ETF Inflow Alert
ETFChannel.com - Tue Apr 15, 10:15AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF where we have detected an approximate $290.9 million dollar inflow -- that's a 6.9%...
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - ZACKS - Mon May 05, 1:49AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Pharma ETFs: A Safe Haven from the Biotech Stock Slump? - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Apr 28, 10:42AM CDT
Why investors may want to think about a play on the pharmaceutical ETFs if they want drug industry exposure.
iShares Nasdaq Biotechnology Index Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.46% Loss
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs.
Pharma ETFs: A Better Healthcare Investment? - Video Blog
Eric Dutram - Zacks Investment Research - Wed Apr 23, 5:42PM CDT
How have pharma ETFs held up during the biotech selloff?
iShares Nasdaq Biotechnology Index Fund (IBB) : Buy @ $231.17
Trading Central - Tue Apr 22, 8:43AM CDT
From a technical view, the ETF is bouncing off a key rising trend line drawn from the bottom of October 2012. Regarding technical indicators, the weekly RSI is pushing above its 50 mark while the 20-week moving average is reversing up. On a...
'Fast Money' Recap: Following the Netflix Story
at The Street - Tue Apr 22, 4:00AM CDT
The trading panel discussed Netflix earnings and Valeant's hostile bid for Allergan.
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 2.33%
Comtex SmarTrend(R) - Mon Apr 21, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $221.37 to a high of $227.34. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $226.39 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
The ongoing market correction has taken a serious toll on biotech stocks, especially among companies early in their development. The iShares Nasdaq Biotech Index , for instance, is down over 15% in the past month alone. Market corrections (and bull...
'Fast Money' Recap: Watch Where Bonds Are Headed
at The Street - Fri Apr 18, 4:00AM CDT
The trading panel discussed bonds, industrial stocks, Chipotle Mexican Grill and IBM.
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's...
IBB, CELG, BIIB, ALXN: ETF Inflow Alert
ETFChannel.com - Tue Apr 15, 10:15AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF where we have detected an approximate $290.9 million dollar inflow -- that's a 6.9%...
